Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabe- tes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849 1861. 320. ZhouYH,Ye XF,Yu FF, Zhang X, QinYY, Lu J, He J. Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke preven- tion. BMC Neurol. 2013;13:1. 321. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134 2141. 322. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocar- dial infarction, and stroke in high risk patients. BMJ. 2002;324:71 86. 323. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the inci- dence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2011;10:25. 324. Kobzar G, Mardla V, Samel N. Short-term exposure of platelets to glu- cose impairs inhibition of platelet aggregation by cyclooxygenase inhibi- tors. Platelets. 2011;22:338 344. 325. Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta- analysis. J Gen Intern Med. 2011;26:1336 1344. 326. Manolio TA, Kronmal RA, Burke GL, O Leary DH, Price TR. Short- term predictors of incident stroke in older adults: the Cardiovascular Health Study. Stroke. 1996;27:1479 1486. 327. Rodriguez BL, D Agostino R, Abbott RD, Kagan A, Burchfiel CM, Yano K, Ross GW, Silbershatz H, Higgins MW, Popper J, Wolf PA, Curb JD. 